Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula

Flu Clinical Trial

Official title:

A Randomized, Controlled Trial of Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06158659
• Other study ID #: 22-SM-11-FEIHE-002
• Status: Recruiting
• Phase: N/A
• Start date: November 14, 2023
• Est. completion date: April 30, 2025

Study information

• Verified date: January 2024
• Source: Heilongjiang Feihe Dairy Co. Ltd.
• Contact: Charlie Zhang, MD
• Phone: +8613901981272
• Email: charlie.zhang[@]sprimmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this interventional clinical trial is to test the effectiveness of enhancing immunity in newly born infants fed with Feihe investigational formula product containing Lactoferrin fortified with HMO. The main question it aims to answer is: - whether the immunity functions of participants in terms of frequency of catching flu and cold in the study product arm is significantly better than participants assigned in the other two arms. 240 qualified participants will be randomized to 3 arms (investigational formula, control formula, and breast-feeding) to consume assigned formula or breast-feeding for 12 months according to protocol. There will be up to 6 site visits arranged for each participant during the study, and all relevant clinical and questionnaire data, including the most important primary outcome - frequency of catching flu and cold for each visit interval, will be captured, recorded and entered to CMTS (Clinical Management Trial System) for statistical analysis and reporting. Researchers will compare the three arms to validate the assumption that the consumption of Feihe investigational formula product containing Lactoferrin fortified with HMO will improve immunity in newly born infants, along with physical development.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 240
• Est. completion date: April 30, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Day to 28 Days

Eligibility

Inclusion Criteria:

• Newborn baby, study entry before weaning (within 28 days of birth)
• Exclusively formula for at least 3 days fed prior to onset of study period.
• Gestational age of 37-42 weeks (36 weeks and six days is considered 36 weeks gestational age).
• Birth weight of 2500g (5 lbs. 8 oz.) or more.
• Signed informed consent obtained for infant's participation in the study.
• Parent or guardian of the infant agrees to not enroll the infant in another interventional clinical research study while participating in this study.

Exclusion Criteria:

• History of underlying metabolic or chronic disease; congenital malformation; or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the infant to ingest food, the normal growth and development of the infant, or the evaluation of the infant.
• Evidence of feeding difficulties or formula intolerance, such as vomiting or poor intake, at time of randomization (at investigator discretion).
• Evidence of growth problems or concern for growth.
• Infant was born large for gestational age (LGA) (defined as birth weight-for-age exceeding 90th percentile as plotted on the growth chart provided by Feihe) from mother who was diabetic at childbirth.
• Participant is immunocompromised (according to a doctor's diagnosis of immunodeficiency such as Combined Immunodeficiencies, DiGeorge Syndrome, Wiskott-Aldrich Syndrome, Severe Congenital Neutropenia and Secondary Immunodeficiencies linked to HIV infection, Down Syndrome or others) and children with known head/brain disease/injury.
• Use of probiotics/prebiotics before and during the study.

Related Conditions & MeSH terms

• Cold
• Flu

Intervention

Dietary Supplement:
• Feihe Investigational Formula
Participants in this arm will receive stage 1 and stage 2 Feihe investigational formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.
• Control Formula
Participants in this arm will receive stage 1 and stage 2 Control formulas. At the first (up to) 6 months, they will be fed with stage1 formula, and then switch to stage 2 formula until 12 months.

Other:
• Breastfeeding
Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.

Locations

Country	Name	City	State
China	Kaitai Scientific Lab	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Heilongjiang Feihe Dairy Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of flu and cold during the study	Frequency of flu and cold that participants caught during the study, which has positive relationship with immunology outcomes.	At the age of 12 months
Secondary	Weight in grams	The weight measurement (gram) of the participant for each site visit	At the age of 15-28 days and 3, 6, 9, 12 months]
Secondary	Height in cm	The height measurement (cm) of the participant for each site visit	At the age of 15-28 days and 3, 6, 9, 12 months
Secondary	Head circumference in cm	The head circumference measurement (cm) of the participant for each site visit	At the age of 15-28 days and 3, 6, 9, 12 months
Secondary	Amount of formula intake in ml	The 24-Hour dietary recall of Formula intake (amount in ml of study formula, any other infant formula or milk consumed) of the participant for each site visit	At the age of 15-28 days and 3, 6, 9, 12 months
Secondary	Stool Characteristics Questionnaire	The frequency of bowel movements and the rating score (0-5) of the stool consistency over the 24-hour period. The rating score of the stool consistency from the stool picture: 0-No bowel movement; Hard- dry, hard pellets; Formed- definite shape, not dry; Soft-no definite shape, pasty; Unformed or seedy- no shape, some water or small lumps ; Waterly- no shape, mainly water where the score of 0-1 represents poor stool characteristics, while 2-5 represents fine stool characteristics.	At the age of 15-28 days and 3, 6 months
Secondary	Medically-confirmed adverse events	The frequency of medically-confirmed adverse events occurred during the study	baseline day to 12 months